Marker Therapeutics Inc. has announced a collaboration with Cellipont Bioservices to advance the cGMP manufacturing of their lead Multi-Antigen Recognizing $(MAR)$-T cell therapy, MT-601, for patients with lymphoma. This partnership aims to support the scale-up and production of MT-601 for the ongoing Phase 1 APOLLO study, which is investigating the therapy in patients with lymphoma who have relapsed after anti-CD19 CAR-T cell therapy or for whom such therapy is not an option. The APOLLO study has already reported favorable safety results and objective responses in 78% of participants, with a 44.4% complete response rate observed in some patients as early as four weeks post-infusion. The collaboration is designed to accelerate clinical supply and prepare for potential pivotal trials and commercial readiness.